ClinicalTrials.gg
RecruitingNCT06666049POCUSUpdated May 5, 2026

Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)

An observational study in Aspiration Pneumonia, sponsored by Clinica Universidad de Navarra, Universidad de Navarra. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Clinica Universidad de Navarra, Universidad de Navarra · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
39
Ages
18 Years to 90 Years
Sex
All
01

Study summary

1. Introduction

Scheduled surgery requires patients to undergo a preoperative fasting period of at least 6 hours to reduce the risk of perioperative pulmonary aspiration. However, certain medications and conditions may delay gastric emptying, potentially increasing aspiration risk. These include diabetic gastroparesis and the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity.

GLP-1 receptor agonists are widely used due to their beneficial effects on glycemic control and weight reduction. However, one of their known effects is delayed gastric emptying, which may result in increased residual gastric content despite adherence to standard fasting guidelines. Recent reports have described cases of pulmonary aspiration during anesthesia in patients receiving GLP-1 receptor agonists, even after appropriate fasting.

Given the increasing use of these medications, there is a need for objective assessment tools to evaluate gastric content in the perioperative setting. Gastric ultrasonography has emerged as a non-invasive bedside technique that may help identify patients at increased risk of aspiration and guide airway management strategies.

Read the detailed description

2. Hypothesis

Gastric ultrasonography performed by trained anesthesiologists is a useful tool for assessing gastric content and may support clinical decision-making in airway management in patients treated with GLP-1 receptor agonists.

3. Methodology

This is a prospective, observational cohort study conducted at participating centers.

The study population consists of adult patients undergoing scheduled surgery under general anesthesia following a standard preoperative fasting period.

Inclusion criteria:

  • Patients receiving treatment with GLP-1 receptor agonists
  • Age ≥18 years
  • Scheduled surgery after a fasting period between 6 and 8 hours
  • ASA physical status I-III
  • Ability to provide informed consent

Exclusion criteria:

  • History of esophagogastric pathology or prior upper abdominal surgery
  • Hiatal hernia or gastroesophageal reflux disease
  • Autonomic nervous system disorders
  • Neurological or neuromuscular diseases
  • Use of medications affecting gastric emptying (e.g., opioids or prokinetics)
  • Pregnancy
  • Presence of clinically significant arrhythmias

    4. Description of the Intervention

Immediately prior to anesthesia induction, gastric ultrasonography will be performed by trained investigators at participating centers, with the patient in both supine and right lateral decubitus positions.

Qualitative, semi-quantitative, and quantitative assessments of gastric content and volume will be performed according to the methodology described by Perlas et al. Data will be recorded in a standardized study database.

Anesthetic and surgical management will proceed according to routine clinical practice.

5. Ethical, Legal, and Economic Considerations

Written informed consent will be obtained from all participants prior to study inclusion.

This is an observational study with no modification of standard clinical care. No additional risks beyond routine clinical practice are anticipated.

Gastric ultrasonography will be performed using equipment available at participating centers, and no additional costs are expected.

6. Results

Study data will be analyzed by the investigators. Results will be disseminated through scientific publications and presentations.

02

Conditions studied

  • Aspiration Pneumonia

Browse trials for

Keywords

  • Bronchopulmonary complications
  • Ultrasound
03

In context

Pneumonia, Aspiration

72 studies on the registry are indexed under Pneumonia, Aspiration; 11 are open to participants now.

This study's planned enrollment of 39 is below the median of 91 across 27 observational studies indexed under Pneumonia, Aspiration.

Browse Pneumonia, Aspiration studies →

Lead sponsor

Clinica Universidad de Navarra, Universidad de Navarra is the lead sponsor of 160 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The reference population will consist of patients undergoing scheduled surgery with a conventional preoperative fasting period (at least 6 hours).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults patients ,, taking GLP-1 analog medications, undergoing scheduled surgery.

Exclusion criteria

Exclusion Criteria:

  1. - History of esophagogastric pathology or previous abdominal surgery.
  2. - Hiatal hernia/gastroesophageal reflux disease.
  3. - Autonomic nervous system disorders.
  4. - Neurological or neuromuscular diseases.
  5. - Use of medications/drugs that affect autonomic regulation and delay gastric emptying (opioids) or potentiate it (prokinetics).
  6. - Pregnancy.
  7. - Presence of arrhythmias.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
39 participants (estimated)
Patient registry
No

Groups and cohorts

  • Treatment with GLP-1 agonists

    Patients undergoing treatment with GLP-1 agonists, from any geographical area, who choose to undergo scheduled and/or urgent surgery under general anesthesia and/or sedation at our hospital over a two-year period (2024-2025).

    Diagnostic Test: Gastric Ultrasound

Interventions

  • Diagnostic testGastric Ultrasound

    Gastric Ultrasound

06

What researchers measure

Primary outcomes

  1. Gastric Ultrasound

    Gastric ultrasonography performed by trained anesthesiologists, for measuring gastric content in volume (cm3) is a useful tool for assessing gastric content and making clinical decisions regarding airway management.

    Time frame: Immediately prior to induction of anesthesia

Secondary outcomes

  1. weight in kilograms

    Weight in kilograms

    Time frame: Immediately prior to induction of anesthesia

  2. Height in centimeters

    Height in centimeters

    Time frame: Immediately prior to induction of anesthesia

  3. BMI in kg/m^2

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: Immediately prior to induction of anesthesia

07

Study locations

2 of 2 sites recruiting
  • Clinica Universidad Navarra
    Madrid, Madrid 28027, Spain
    Recruiting
    • Miguel Angel Fernandez-Vaquero, MD,PhD · Contactmfvaquero@unav.es · 0034913531920
  • CAUSA Salamanca
    Salamanca, Spain
    Recruiting
    • Jose Alfonso Sastre · Contact
    • Jose Alfonso Sastre · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06666049
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Oct 21, 2024
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Carlos Puga Carrasco, MD
Contact
cpuga@unav.es
0034913531920 ext. 7633
Miguel Angel Fernandez-Vaquero, MD,PhD
Contact
mferva7@gmail.com
0034913531920 ext. 7633

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion